Abbvie Korea’s lead product line Humira is facing an insurance price cut of 30%. This ex officio adjustment by the government is to be made due to the introduction of the two biosimilars earlier this year by Samsung Bioepis, including its Adalloce prefilled pen inj..

The Ministry of Health and Welfare (MOHW) is preparing to amend the 'drug benefit list and price ceiling schedule' to include such adjustments. Once the amendment is finalized, it will take effect from the 7th of this month.

Humira is a biologic product approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis, and Crohn’s disease, etc. Humira is facing price adjustments in Korea as S